Abstract
We examined the impact of three lipid lowering drugs on fat oxidation during a 120 minute treadmill walk, at an exercise intensity of 50% maximal oxygen uptake (VO2 max). Subjects (N = 24) were healthy male volunteers with normal serum chemistry, assigned to three groups (n = 8). Group A received simvastatin 20 mg twice daily, Group B received gemfibrozil 600 mg twice daily, Group C received acipimox 600 mg twice daily. Each subject performed two 120 minute walks, once with drug, and once with placebo (4 days treatment plus a final dose on the morning of the exercise trial). Treatment order was reversed for half of each group. Compared to placebo, simvastatin treatment, had no impact on fat oxidation (40.9 +/- 8.6% vs 40.9 +/- 9.7%), or on plasma concentration of free fatty acids (FFA), glycerol or glucose. Treatment with gemfibrozil, showed lower fat oxidation (32.3 +/- 13.9% vs 39.7 +/- 7.9%), and lower plasma concentrations of FFA and glycerol, but differences did not reach significance at the 0.05 level. Acipimox treatment, produced significantly lower fat oxidation (36.9 +/- 12.8% vs 50.2 +/- 16.1%, P = 0.011), and lower plasma concentrations of FFA and glycerol (P = < 0.0001 and P = < 0.0001, respectively). Plasma glucose showed a trend toward lower values with acipimox (P = 0.088). These data demonstrate that selective lipid lowering drugs can reduce fat availability for exercise metabolism, placing increased demands on carbohydrates which may reduce exercise tolerance.
Full text
PDF






Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ahlborg G., Felig P., Hagenfeldt L., Hendler R., Wahren J. Substrate turnover during prolonged exercise in man. Splanchnic and leg metabolism of glucose, free fatty acids, and amino acids. J Clin Invest. 1974 Apr;53(4):1080–1090. doi: 10.1172/JCI107645. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Alberts A. W., Chen J., Kuron G., Hunt V., Huff J., Hoffman C., Rothrock J., Lopez M., Joshua H., Harris E. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A. 1980 Jul;77(7):3957–3961. doi: 10.1073/pnas.77.7.3957. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bergström J., Hultman E., Jorfeldt L., Pernow B., Wahren J. Effect of nicotinic acid on physical working capacity and on metabolism of muscle glycogen in man. J Appl Physiol. 1969 Feb;26(2):170–176. doi: 10.1152/jappl.1969.26.2.170. [DOI] [PubMed] [Google Scholar]
- Boobis L. H., Maughan R. J. A simple one-step enzymatic fluorometric method for the determination of glycerol in 20 microliters of plasma. Clin Chim Acta. 1983 Aug 15;132(2):173–179. doi: 10.1016/0009-8981(83)90245-0. [DOI] [PubMed] [Google Scholar]
- Brown W. V. Review of clinical trials: proving the lipid hypothesis. Eur Heart J. 1990 Dec;11 (Suppl H):15–20. doi: 10.1093/eurheartj/11.suppl_h.15. [DOI] [PubMed] [Google Scholar]
- Frick M. H., Elo O., Haapa K., Heinonen O. P., Heinsalmi P., Helo P., Huttunen J. K., Kaitaniemi P., Koskinen P., Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 Nov 12;317(20):1237–1245. doi: 10.1056/NEJM198711123172001. [DOI] [PubMed] [Google Scholar]
- Fuccella L. M., Goldaniga G., Lovisolo P., Maggi E., Musatti L., Mandelli V., Sirtori C. R. Inhibition of lipolysis by nicotinic acid and by acipimox. Clin Pharmacol Ther. 1980 Dec;28(6):790–795. doi: 10.1038/clpt.1980.236. [DOI] [PubMed] [Google Scholar]
- Greenleaf J. E., Van Beaumont W., Brock P. J., Morse J. T., Mangseth G. R. Plasma volume and electrolyte shifts with heavy exercise in sitting and supine positions. Am J Physiol. 1979 Mar;236(3):R206–R214. doi: 10.1152/ajpregu.1979.236.3.R206. [DOI] [PubMed] [Google Scholar]
- Hagemenas F. C., Pappu A. S., Illingworth D. R. The effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolaemia. Eur J Clin Invest. 1990 Apr;20(2):150–157. doi: 10.1111/j.1365-2362.1990.tb02262.x. [DOI] [PubMed] [Google Scholar]
- Havel R. J., Pernow B., Jones N. L. Uptake and release of free fatty acids and other metabolites in the legs of exercising men. J Appl Physiol. 1967 Jul;23(1):90–99. doi: 10.1152/jappl.1967.23.1.90. [DOI] [PubMed] [Google Scholar]
- Hermansen L., Hultman E., Saltin B. Muscle glycogen during prolonged severe exercise. Acta Physiol Scand. 1967 Oct-Nov;71(2):129–139. doi: 10.1111/j.1748-1716.1967.tb03719.x. [DOI] [PubMed] [Google Scholar]
- Morris J. N., Clayton D. G., Everitt M. G., Semmence A. M., Burgess E. H. Exercise in leisure time: coronary attack and death rates. Br Heart J. 1990 Jun;63(6):325–334. doi: 10.1136/hrt.63.6.325. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Walker M., Cooper B. G., Elliott C., Reed J. W., Orskov H., Alberti K. G. Role of plasma non-esterified fatty acids during and after exercise. Clin Sci (Lond) 1991 Sep;81(3):319–325. doi: 10.1042/cs0810319. [DOI] [PubMed] [Google Scholar]
- Wilmore J. H., Costill D. L. Adequacy of the Haldane transformation in the computation of exercise V O2 in man. J Appl Physiol. 1973 Jul;35(1):85–89. doi: 10.1152/jappl.1973.35.1.85. [DOI] [PubMed] [Google Scholar]
- Zimetbaum P., Frishman W. H., Kahn S. Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins. J Clin Pharmacol. 1991 Jan;31(1):25–37. doi: 10.1002/j.1552-4604.1991.tb01883.x. [DOI] [PubMed] [Google Scholar]
